- Capital Cube•2 days ago
UCB SA : UCBJY-US: Dividend Analysis : May 02nd, 2017 (record date) : By the numbers : April 28, 2017
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing UCB SA with the following peers – Amgen Inc., Shire PLC Sponsored ADR, Pfizer Inc., Biogen Inc., Novartis AG Sponsored ADR and Catalyst Pharmaceuticals, Inc. (AMGN-US, SHPG-US, PFE-US, BIIB-US, NVS-US and CPRX-US). UCB SA’s dividend yield is 1.03 percent and its dividend payout is 24.00 ... Read more (Read more...)
- PR Newswire•9 days ago
Data being presented include posters further describing the efficacy and tolerability profile of VIMPAT® (lacosamide) CV and BRIVIACT® (brivaracetam) CV. Posters will be presented describing the efficacy and tolerability of lacosamide monotherapy in elderly newly diagnosed epilepsy patients and in newly diagnosed epilepsy patients with psychiatric comorbidities. Pooled results from long-term follow-up studies of adjunctive brivaracetam in patients with secondarily generalized tonic-clonic seizures and a poster comparing the healthcare utilization and direct medical costs in newly diagnosed epilepsy patients compared to a non-epilepsy population will also be presented.
- PR Newswire•19 days ago
ATLANTA, April 11, 2017 /PRNewswire/ -- The Epilepsy Foundation of Georgia (EFGA), with sponsorship from UCB, Inc., a biopharmaceutical company, had the pleasure of hosting Georgia Labor Commissioner Mark Butler and Atlanta-area business at the EFWorks Employer Forum. Attendees included companies large and small.
UCBJY: Summary for UCB UNSP ADR EACH REPR 0.5 ORD - Yahoo Finance
UCB SA (UCBJY)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
|Day's range||0.00 - 0.00|
Trade prices are not sourced from all markets
|PE ratio (TTM)||27.19|
|Dividend & yield||0.62 (1.55%)|
|1y target est||N/A|